Skip to main content

Table 3 Initial recurrence patterns and treatment for recurrence

From: Prognoses, outcomes, and clinicopathological characteristics of very elderly patients with hepatocellular carcinoma who underwent hepatectomy

 Group VE (n = 49)Group E (n = 363)Group Y (n = 384)p; VE vs. Ep; VE vs. Y
Recurrence cases (%)49 (24)64 (231)68 (261)0.04< 0.01
Median recurrence duration (months) (range)11 (3–68)11 (0.4–111)9 (0.2–197)0.980.39
Recurrence site(n = 24)(n = 231)(n = 261)  
 Liver (%)75 (18)83 (192)82 (213)0.320.42
 Lung (%)33 (8)18 (41)29 (75)0.060.63
 Adrenal glands (%)8 (2)2 (5)5 (14)0.070.54
 Bone (%)13 (3)11 (25)10 (27)0.800.74
Treatment for recurrence(n = 24)(n = 231)(n = 261)  
 Rehepatectomy (%)0 (0)6 (15)46 (119)0.19< 0.01
 Liver transplantation (%)0 (0)0 (0)3 (8)-0.38
 RFA/MCT (%)33 (8)25 (57)18 (46)0.350.06
 TACE (%)63 (15)52 (121)47 (122)0.340.13
 Resection of metastases (%)13 (3)3 (7)5 (13)0.020.12
 Systemic chemotherapy including molecular target drug (%)17 (4)23 (53)33 (85)0.480.10
 Radiation (%)17 (4)12 (27)16 (43)0.470.98
  1. VE very elderly group, E elderly group, Y young group, RFA radiofrequency ablation, MCT microwave coagulation therapy, transcatheter arterial chemoembolization